Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE
Status:
Completed
Trial end date:
2019-12-26
Target enrollment:
Participant gender:
Summary
This was a multicenter, randomized (1:1 inhaled treprostinil: placebo), double-blinded,
placebo-controlled trial to evaluate the safety and efficacy of inhaled treprostinil in
subjects with pre-capillary pulmonary hypertension (PH) associated with interstitial lung
disease (ILD) including combined pulmonary fibrosis and emphysema (CPFE). The study included
326 patients at approximately 120 clinical trial centers. The treatment phase of the study
lasted approximately 16 weeks. Patients who completed all required assessments were eligible
to enter an open-label, extension study (RIN-PH-202).